documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig lexiscan registered trademark astellas us llc macugen registered trademark bausch health ireland limited symtuza registered trademark janssen sciences ireland uc tamiflu registered trademark hoffmannla roche inc report also refers trademarks service marks trade names companiesthis annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item annual report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include viral diseases inflammatory fibrotic diseases oncology seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations principal products innovative medicines represent advancements offering enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects greater efficacy focus innovation allowed us deliver marketed products across multiple therapeutic areas principal products approved indications united states follows hivaids biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy single tablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine tenofovir alafenamide taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications emtricitabine taf descovy also approved us food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquired hiv infection certain atrisk patients odefsey oral formulation dosed day treatment hiv infection certain patients odefsey single tablet regimen fixeddose combination antiretroviral medications emtricitabine taf rilpivirine marketed janssen sciences ireland uc one janssen pharmaceutical companies johnson johnson janssen genvoya oral formulation dosed day treatment hiv infection certain patients genvoya single tablet regimen fixeddose combination antiretroviral medicines elvitegravir cobicistat emtricitabine taf stribild oral formulation dosed day treatment hiv infection certain patients stribild single tablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tenofovir disoproxil fumarate tdf emtricitabine compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medications tdf emtricitabine janssens rilpivirine hydrochloride atripla oral formulation indicated complete regimen treatment hiv infection certain patients atripla fixeddose combination antiretroviral medications tdf emtricitabine bristolmyers squibb company bmss efavirenz truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients fixed dose combination antiretroviral medications tdf emtricitabine truvada also approved fda prep indication combination safer sex practices reduce risk sexually acquired hiv infection certain atrisk patients liver diseases vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hepatitis c virus hcv infection adults genotype previously treated nsa inhibitorcontaining regimen ii genotype previously treated sofosbuvircontaining regimen without nsa inhibitor epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii adults genotype infection decompensated cirrhosis combination ribavirin iii adults genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin iv certain pediatric patients genotype without cirrhosis compensated cirrhosis vemlidy oral formulation taf dosed day treatment chronic hepatitis b virus hbv infection adults compensated liver disease viread oral formulation tdf dosed day treatment chronic hbv infection adults certain pediatric patients hematologyoncology yescarta axicabtagene ciloleucel chimeric antigen receptor car cell therapy treatment adult patients relapsed refractory large b cell lymphoma two lines systemic therapy including diffuse large bcell lymphoma dlbcl otherwise specified primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arising follicular lymphoma zydelig idelalisib oral formulation kinase inhibitor treatment patients relapsed chronic lymphocytic leukemia cll combination rituximab rituximab alone would considered appropriate therapy due comorbidities ii relapsed follicular bcell non hodgkin lymphoma fl patients received least two prior systemic therapies iii relapsed small lymphocytic lymphoma received least two prior systemic therapies letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults information product revenues including amount revenue contributed products listed last three fiscal years see note revenues notes consolidated financial statements included part ii item annual report commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products united states exclusively wholesale channel product sales three large wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues sell distribute products europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected description competitors see item risk factors face significant competition research development research development rd philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources internal rd opportunities external business development activity product development efforts focused primarily viral diseases inflammatory fibrotic diseases oncology research scientists engaged discovery development new molecules technologies hope lead approval new medicines advance current standard care address unmet medical needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process continued invest advance rd pipeline across therapeutic areas end rd pipeline included active clinical studies phase clinical trials summary key product candidates corresponding current stages development product candidates viral diseases product candidates description phase gs gs capsid inhibitor evaluated treatment hiv infection selgantolimod selgantolimod tlr agonist evaluated treatment chronic hbv infection phase vesatolimod vesatolimod tlr agonist evaluated potential cure hiv infection elipovimab elipovimab broadly neutralizing antibody evaluated potential cure hiv infection gs gs pdl inhibitor evaluated treatment chronic hbv infection product candidates inflammatory fibrotic diseases product candidates description phase filgotinib filgotinib jak inhibitor evaluated treatment crohns disease ii ulcerative colitis iii psoriatic arthritis cilofexor cilofexor fxr agonist evaluated treatment primary sclerosing cholangitis glpg glpg autotaxin inhibitor evaluated treatment idiopathic pulmonary fibrosis phase filgotinib filgotinib evaluated treatment ankylosing spondylitis ii uveitis gs gs tpl inhibitor evaluated treatment ulcerative colitis glpg glpg adamts inhibitor evaluated treatment osteoarthritis selonsertib selonsertib ask inhibitor evaluated treatment diabetic kidney disease cilofexor firsocostat selonsertib combinations cilofexor firsocostat acc inhibitor selonsertib combinations evaluated treatment nonalcoholic steatohepatitis nash glpg glpg evaluated treatment systemic sclerosis glpg glpg gpr inhibitor evaluated treatment idiopathic pulmonary fibrosis phase glpg glpg evaluated treatment inflammatory diseases glpg glpg evaluated treatment inflammatory diseases glpg glpg evaluated treatment inflammatory diseases glpg glpg evaluated treatment inflammatory diseases product candidates oncology product candidates description phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment second line dlbcl phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel also evaluated treatment first line dlbcl ii dlbcl combination either rituximab lenalidomide ktex ktex car cell therapy evaluated treatment adult pediatric acute lymphoblastic leukemia ii cll phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment dlbcl combination utomilumab kite kite mage aa evaluated treatment solid tumors kite kite hpv e evaluated treatment solid tumors gs gs bispecific antibody evaluated treatment solid tumors gs gs oral pdl inhibitor evaluated treatment solid tumors agen agen bispecific mab evaluated treatment multiple indications oncology agen agen anticd mab evaluated treatment multiple indications oncology optionable partner program optioned partner program addition internal discovery clinical development programs seek add portfolio products product acquisition inlicensing strategic collaborations completed strategic partnerships licensing deals equity investments reflects commitment developing pipeline across range diseases address areas significant unmet medical need positioning longterm growth business patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents phase product candidates product candidates fixeddose combinations single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration us eu product candidates inflammatory fibrotic diseases filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis psoriatic arthritis glpg treatment idiopathic pulmonary fibrosis cilofexor treatment primary sclerosing cholangitis product candidate oncology axicabtagene ciloleucel treatment second line dlbcl composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite gilead company following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents principal products products fixeddose combinations single tablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu letairis ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted gilead watson laboratories inc reached agreement settle patent litigation matter related letairis gilead lupin limited reached agreement settle patent litigation matter related ranexa gilead teva pharmaceuticals reached agreement settle patent litigation concerning patents protect emtricitabine truvada atripla products additional information see item risk factors face significant competition supplementary protection certificates spcs granted several european countries validity spcs challenged several generic manufacturers many launched competing products application patent term extension filed united states granted would extend us expiration date least applications patent term extensions pending united states andor spcs pending one countries european union products composition matter patent expired european union european union united states patent applications pending relating proprietary manufacturing processes kite patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api hiv products well yescarta held third parties acquired exclusive rights patents agreements parties may obtain patents certain products many years marketing approval obtained patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputation may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries description significant pending legal proceedings see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partners cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites yescarta established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities manufacture distribute certain products api clinical andor commercial uses facilities located foster city san dimas la verne oceanside el segundo california dublin cork ireland hoofddorp netherlands edmonton canada foster city california conduct process chemistry research formulation development activities manufacture api drug product clinical trials oversee thirdparty contract manufacturers san dimas la verne california manufacture ambisome also package label majority commercial products distribution americas pacific rim oceanside california utilize facility clinical manufacturing process development biologics candidates el segundo california utilize facility clinical commercial manufacturing processing yescarta cork dublin ireland utilize cork facility commercial manufacturing packaging labeling products also perform quality control testing labeling packaging final release many products distribution european union international markets dublin facility also responsible distribution activities products edmonton canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes hoofddorp netherlands utilize facility commercial manufacturing processing yescarta thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions information thirdparty manufacturers see item risk factors manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies yescarta required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues seasonality operations backlog worldwide product sales reflect significant degree seasonality enduser demand united states fluctuations wholesaler inventory levels impacted product sales observed strong wholesaler subwholesaler purchases products fourth quarter resulted inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds buying patterns impacted product sales recorded particular quarter information see item risk factors inability accurately predict demand products fluctuations purchasing patterns wholesaler inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states european union countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda united states european commission european union well national authorities european union member states must approve drug sold respective country countries general process drug approval united states summarized many countries including countries european union similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application nda supplemental nda fda seeking approval sell drug candidate particular use fdas discretion fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards concerns safety efficacy uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland netherlands also must obtain local licenses permits compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited review european union regulatory system approval process european union eu products subject variety eu eu member state regulations governing clinical trials commercial sales distribution required obtain marketing authorization eu market medicinal products relevant market conduct clinical trials eu governed among others directive ec eu good clinical practice rules impose legal regulatory obligations similar provided applicable us laws conduct clinical trials eu must approved competent authorities eu member states clinical trials take place positive opinion must obtained relevant ethics committee relevant member state eu legislator adopted regulation eu replace directive ec introduce coordinated procedure authorization clinical trials regulation expected apply marketing authorization holders manufacturers importers wholesalers distributors medicinal products placed market eu required comply number regulatory requirements including pharmacovigilance good manufacturing practices compliance requirement obtain manufacturing import andor distribution licenses issued competent authorities eu member states failure comply requirements may lead imposition civil criminal administrative sanctions including suspension marketing manufacturing authorizations pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices result price increases implement time time certain products may limited effect product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature private insurers government payers often reduce amount reimburse providers increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement government agencies third parties may required provide rebates discounts products may result adjustment product revenues pharmaceutical pricing reimbursement pressures may adversely affect profitability results operations inability accurately predict demand products fluctuations purchasing patterns wholesaler inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price patient assistance programs recently enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products health care fraud abuse laws antibribery laws subject various us federal state laws pertaining health care fraud abuse including antikickback laws false claim laws anti kickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing patient support medical activities may subject scrutiny laws similarly europe interactions pharmaceutical companies physicians subject strict laws regulations industry selfregulation codes conduct physicians codes professional conduct applicable including eu member states anti corruption laws uk bribery act addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program us healthcare reform us federal state governments continue propose pass legislation designed regulate healthcare industry including legislation seeks indirectly directly regulate pharmaceutical drug pricing information see item risk factors results operations may adversely affected current potential future healthcare legislative regulatory actions laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future employees january approximately employees believe good relations employees environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements securities exchange act exchange act therefore file periodic reports proxy information statements information sec sec maintains website httpwwwsecgov contains reports proxy information statements information regarding issuers file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales hiv products unable increase maintain hiv sales results operations may adversely affected receive substantial portion revenue sales products treatment prevention hiv infection year ended december sales hiv products accounted approximately total product sales hiv products account higher percentage total product sales hiv products contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine ftc belong nucleoside class antiviral therapeutics treatment paradigm hiv changes causing nucleosidebased therapeutics fall favor unable maintain increase hiv product sales results operations would likely suffer would likely need scale back operations including future drug development spending research development rd efforts addition future sales hiv products depend part extent reimbursement products private public payers may continue experience global pricing pressure could result larger discounts rebates products delayed reimbursement negatively impacts product sales results operations also private public payers choose exclude products formulary coverage lists limit types patients coverage provided would negatively impact demand revenues products change formulary coverage reimbursement levels discounts rebates offered products payers may impact anticipated revenues unable achieve forecasted hiv sales stock price could adversely impacted may unable sustain increase sales hiv products number reasons including limited reasons discussed following products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices physicians see benefit hiv products sales hiv products limited new branded generic products introduced major markets ability maintain pricing market share may affected fail develop commercialize new products expand indications existing products prospects future revenues results operations may adversely affected success business depends ability introduce new products well expand indications existing products address areas unmet medical need launch commercially successful products necessary cover substantial rd expenses offset revenue losses existing products lose market share due various factors competition loss patent exclusivity well provide growth business many difficulties uncertainties inherent drug development introduction new products product development cycle characterized significant investments resources long lead times unpredictable outcomes due nature developing medicines human use expend significant time resources product pipeline without assurance recoup investments efforts commercially successful high rate failure inherent discovery development new products failure occur point process including late process substantial investment example see face risks clinical trials including potential unfavorable results delays anticipated timelines disruption may adversely affect prospects future revenue growth results operations state certainty whether product candidates development approved launched whether able develop license acquire additional product candidates products whether products launched commercially successful failure launch commercially successful new products new indications existing products could material adverse effect future revenues results operations longterm success inability accurately predict demand products fluctuations purchasing patterns wholesaler inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price may unable accurately predict demand products including uptake new products demand depends number factors example nonretail sector united states includes government institutions including state aids drug assistance programs adaps us department veterans affairs correctional facilities large health maintenance organizations tends less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future sell distribute products united states exclusively wholesale channel year ended december approximately product sales united states three wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed addition observed strong wholesaler subwholesaler purchases products fourth quarter typically results inventory drawdown wholesalers subwholesalers subsequent first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues face significant competition face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing tafcontaining hiv products compete primarily products viiv healthcare company viiv also face competition generic hiv products generic versions efavirenz component atripla available united states canada europe observed pricing pressure related efavirenz component atripla sales tdf one active pharmaceutical ingredients truvada atripla compleraeviplera stribild faces generic competition european union united states certain countries addition ftc active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states pursuant settlement agreement relating patents protect truvada atripla teva pharmaceuticals permitted launch generic fixeddose combinations ftc tdf generic fixeddose combinations ftc tdf efavirenz united states september hepatitis c virus hcv products compete primarily products marketed abbvie inc merck co inc hepatitis b virus hbv products face competition existing therapies treating patients hbv well generic versions tdf hbv products also compete products marketed bristolmyers squibb company novartis pharmaceuticals corporation novartis yescarta competes car cell therapy marketed novartis noncar product marketed roche expected compete products companies developing advanced cell therapies yescarta commercial products also face competition certain clinical trials enrolling car eligible patients addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share result new technologies commercialization strategies otherwise could adversely affect results operations stock price may required pay significant damages royalty payments result ongoing litigation related yescarta biktarvy adverse outcomes ongoing litigation related yescarta biktarvy products could require us pay significant monetary damages royalty payments past future sales predict ultimate outcome litigation matters timing magnitude payments could material adverse impact results operations financial condition stock price october juno therapeutics inc sloan kettering cancer center collectively juno filed lawsuit us us district court central district california alleging commercialization axicabtagene ciloleucel sold commercially yescarta infringes us patent patent jury trial held patent december jury found asserted claims patent valid willfully infringed asserted claims patent jury also awarded juno damages amounts million upfront payment running royalty october date jurys verdict parties filed posttrial motions january file briefings first quarter expect judge rule matters later district court issued rulings entered judgment case may appealed us court appeals federal circuit although predict certainty ultimate outcome litigation believe jurys verdict error also believe errors made court respect certain rulings trial jurys verdict upheld appeal loss zero jurys verdict upheld entirety appeal estimate upper end range possible loss december approximately billion consists million upfront payment determined jury ii approximately million represents estimated royalties adjusted revenues yescarta october december iii enhanced damages requested juno two times sum ii result jurys finding willfulness sum excludes costs pre judgment interest supplemental damages consisting royalties sales yescarta december date judgment could subject royalty jurys verdict prospective royalty proposed juno enhancement postjudgment sales yescarta would subject prospective royalties estimated could would payable adjusted yescarta revenues judgment expiry patent august expect judge rule amount prospective royalties enhanced damages course deciding posttrial motions courts determination prospective royalties enhanced damages also appealed jurys verdict upheld appeal amount could required pay juno could significant payment could material adverse impact results operations financial condition stock price february viiv filed lawsuit us us district court delaware alleging commercialization bictegravir sold commercially combination taf ftc biktarvy infringes viivs us patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid court set trial date september lawsuit information litigation well related litigation countries outside united states see note commitments contingencies notes consolidated financial statements included part ii item annual report although predict certainty ultimate outcome litigation adverse judgment could result significant monetary damages royalty payments past future sales could material impact results operations financial condition stock price results operations may adversely affected current potential future healthcare legislative regulatory actions legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently united states affordable care act aca enacted expand healthcare coverage since numerous efforts made repeal amend administratively limit aca whole part example december us court appeals fifth circuit held individual health insurance mandate aca unconstitutional remanded case back district court determine whether provisions aca stand without individual health insurance mandate ongoing challenges aca new legislative proposals resulted uncertainty regarding acas future viability destabilization health insurance market resulting impact business uncertain could material efforts control prescription drug prices could also material adverse effect business example president trump secretary us department health human services hhs released american patients first blueprint begun implementing certain portions initiative includes proposals increase generic drug biosimilar competition enable medicare program negotiate drug prices directly improve transparency regarding drug prices lower consumers outofpocket costs trump administration also proposed establish international pricing index would used benchmark determine costs potentially limit reimbursement drugs medicare part b addition december us food drug administration fda issued proposal implement two pathways legal importation certain prescription drugs canada prescription drugs fdaapproved manufactured abroad authorized sale foreign country originally intended sale foreign country among pharmaceutical manufacturer industryrelated proposals congress proposed bills change medicare part benefit impose inflationbased rebate medicare part alter benefit structure increase manufacturer contributions benefit phases volume drug pricingrelated bills dramatically increased current congress resulting impact business uncertain could material addition majority states enacted legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring biopharmaceutical manufacturers publicly report proprietary pricing information creating review boards recommending price caps means controlling prices pharmaceutical products purchased state agencies example californias governor signed prescription drug price transparency state bill law requiring prescription drug manufacturers provide advance notice explanation price increases certain drugs exceed specified threshold many states proposed enacted similar legislation addition many state legislatures considering already passed various bills would reform drug purchasing price negotiations facilitate import lowerpriced drugs outside united states encourage use generic drugs initiatives legislation may cause added pricing pressures products changes medicaid program federal state level could also material adverse effect business proposals could impact coverage reimbursement products including giving states flexibility manage drugs covered medicaid program could material adverse effect limiting products use coverage furthermore state medicaid programs could request additional supplemental rebates products many reasons extent private insurers managed care programs follow medicaid coverage payment developments could use enactment increased rebates exert pricing pressure products adverse effects may magnified adoption lower payment schedules proposed regulatory actions affecting manufacturers could material adverse effect business difficult predict impact proposed legislative regulatory actions resulting state actions use reimbursement products united states actions may adversely affect results operations many countries outside united states including european union eu member states established complex lengthy procedures obtain price approvals coverage reimbursement many eu member states review periodically decisions concerning pricing reimbursement medicinal products outcome review predicted could adverse effect pricing reimbursement medicinal products eu member states reductions pricing medicinal products one eu member state could affect price eu member states negative impact financial results existing products subject reimbursement government agencies third parties may required provide rebates discounts products may result adjustment product revenues pharmaceutical pricing reimbursement pressures may adversely affect profitability results operations successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services substantial portion product sales subject significant discounts list price including rebates may required pay certain governmental agencies addition standard reimbursement structures may adequately reimburse innovative therapies example fiscal year centers medicare medicaid services cms established medicare inpatient reimbursement yescarta includes payment severity adjusted diagnosis related group drg new technology addon payment ntap yescarta cover cost yescarta may cover less cases outlier payment taken together total payment may sufficient reimburse hospitals cost care patients receiving yescarta cms also made decision much pay yescarta fiscal year beyond medicare adequately reimburse cost yescarta could impact willingness hospitals offer therapy doctors recommend therapy could lessen attractiveness therapy patients could adverse effect sales yescarta results operations additionally european union barriers reimbursement individual countries could limit uptake yescarta addition estimate rebates required pay connection sales particular quarter based claims data prior quarters united states actual rebate claims typically made payers one three quarters arrears actual claims payments may vary significantly estimates cause adjustment product revenues extent actual anticipated product revenues fall short investors expectations stock price could adversely impacted information concerning eu pricing reimbursement regime please see results operations may adversely affected current potential future healthcare legislative regulatory actions laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting health care fraud abuse data privacy security united states laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute individual state laws relating pricing sales marketing practices health insurance portability accountability act hipaa federal state laws relating privacy security health information violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state health care programs including medicare medicaid veterans administration health programs federal employee health benefit programs actions executives overseeing business significant remediation measures addition laws regulations broad scope subject change evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices violations laws allegations violations could also result negative publicity consequences could harm reputation disrupt business adversely affect results operations events occur business stock price could materially adversely affected recently enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products addition government price reporting payment regulations complex continually assessing methods calculate report pricing accordance obligations methodologies calculations inherently subjective may subject review challenge various government agencies may disagree interpretation government disagrees reported calculations may need restate previously reported data could subject additional financial legal liability described description government investigations related litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report yescarta chimeric antigen receptor car cell therapy represents novel approach cancer treatment creates significant challenges us may impact ability increase sales yescarta yescarta car cell therapy involves harvesting cells patients blood ii engineering cells express cancerspecific receptors iii increasing number engineered cells iv infusing functional cancerspecific cells back patient advancing novel personalized therapy creates significant challenges including educating certifying medical personnel regarding procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy program required fda yescarta using medicines manage adverse side effects therapy tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impact efficacy treatment developing robust reliable process limiting contamination risks engineering patients cells ex vivo infusing engineered cells back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community may able establish demonstrate medical community commercial governmental payers safety efficacy yescarta potential advantages compared existing future therapeutics challenges related reimbursement yescarta see also existing products subject reimbursement government agencies third parties may required provide rebates discounts products may result adjustment product revenues pharmaceutical pricing reimbursement pressures may adversely affect profitability results operations fail overcome significant challenges sales yescarta results operations stock price could adversely affected engaged may future engage business acquisitions licensing arrangements collaborations disposals assets strategic transactions could cause us incur significant expenses could adversely affect financial condition results operations engaged may future engage business acquisitions licensing arrangements collaborations disposals assets transactions part business strategy may identify suitable transactions future may complete transactions timely manner costeffective basis may realize expected benefits example successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated also may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities also acquired may future acquire equity investments strategic transactions connection collaboration galapagos nv value equity investments may fluctuate decline value conduct annual impairment testing goodwill indefinitelived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles may result impairment charges example fourth quarter recognized million million respectively impairment charges related indefinitelived intangible assets acquired connection acquisition kite pharma inc fail overcome risks could cause us incur significant expenses negatively affect profitability could adverse effect results operations could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment long term assets face risks associated global operations may adversely affect financial condition results operations operations outside united states accompanied certain financial political economic risks including listed foreign currency exchange approximately product sales outside united states significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar use foreign currency exchange forward options contracts hedge percentage forecasted international sales hedging program eliminate exposure currency fluctuations predict future fluctuations foreign currency exchange rates us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline antibribery subject us foreign corrupt practices act similar worldwide antibribery laws govern international operations respect payments government officials international operations heavily regulated require significant interaction foreign officials though policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom possible certain practices may challenged laws addition despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents enforcement activities antibribery laws could subject us administrative legal proceedings actions could result civil criminal sanctions including monetary penalties exclusion health care programs risks inherent conducting global business include international operations including use thirdparty manufacturers distributors collaboration arrangements outside united states expose us increased risk theft intellectual property proprietary technology particularly jurisdictions less robust intellectual property protections united states well restrictive government actions intellectual property foreign assets nationalization expropriation imposition compulsory licenses may subject protective economic policies taken foreign governments trade protection measures import export licensing requirements may result imposition trade sanctions similar restrictions united states governments operations may adversely affected instability disruption destruction geographic region operate regardless cause including war terrorism social unrest political changes instability example january united kingdom uk withdrew european union eu initiated transition period uk eu negotiate future relationship uncertainty concerning changes laws regulations governing conduct clinical trials marketing medicinal products uk following countrys exit eu uncertainty may lead significant complexity risks company ability research develop market medicinal products eu uk see also business disruptions natural manmade disasters may adversely affect revenues materially reduce earnings encounter risks global operations may adversely affected could adverse effect overall business results operations significant safety issues arise marketed products product candidates reputation may harmed future sales may reduced could adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time patients underlying health problems medicines expect continue finding new issues related safety resistance drug interactions issues may require changes product labels additional warnings contraindications even narrowed indications occur could reduce market acceptance sales products regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations could adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda european medicines agency ema comparable regulatory agencies countries continuing clinical trials many products currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing safety reporting promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk certain circumstances may required implement risk evaluation mitigation strategy program products could include medication guide patient package insert communication plan healthcare providers restrictions distribution use product elements fda deems necessary assure safe use drug failure comply requirements imposed fda could result significant civil monetary penalties operating results may adversely affected face risks clinical trials including potential unfavorable results delays anticipated timelines disruption may adversely affect prospects future revenue growth results operations required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products example february announced kite program antib cell maturation antigen evaluated treatment multiple myeloma would moving forward also recently announced stellar stellar phase studies evaluating safety efficacy selonsertib treatment nonalcoholic steatohepatitis nash meet prespecified week primary endpoints product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth results operations may adversely impacted example face numerous risks uncertainties product candidates including filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis psoriatic arthritis glpg treatment idiopathic pulmonary fibrosis cilofexor treatment primary sclerosing cholangitis axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth results operations may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn adversely affect results operations harm business addition extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals may adversely affected depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories example collaboration arrangements janssen sciences ireland uc odefsey compleraeviplera symtuza countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline addition rely thirdparty sites collect patients white blood cells known apheresis centers shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta patients disruption difficulties encountered vendors could result product loss regulatory action harm yescarta business reputation ensure apheresis center prepared ship cells manufacturing facilities plan conduct quality certifications apheresis center however apheresis centers may choose participate certification process may unable complete certification timely manner could delay restrain manufacturing commercialization efforts result sales yescarta may limited could harm results operations success depends significant degree ability defend patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents proprietary rights important business success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications addition competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office uspto proceedings determine right patent validity patent granted litigation postgrant proceedings uspto proceedings unpredictable expensive could divert management attention operations even ultimately successful results operations may adversely affected events generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report entry generic versions products may future lead market share price erosion negative impact business results operations success depends large part ability operate without infringing upon patents proprietary rights third parties found infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned third parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir see may required pay significant damages royalty payments result ongoing litigation related yescarta biktarvy see also description litigation regarding sofosbuvir axicabtagene ciloleucel bictegravir tdf taf combination ftc use preexposure prophylaxis note commitments contingencies notes consolidated financial statements included part ii item annual report furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets internal knowhow technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties could cause delays clinical trials applications regulatory approval may write costs manufacturing batch fails pass quality inspection meet regulatory approval addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products may able locate additional replacement facilities reasonable basis sales products could also adversely impacted reliance limited number facilities extent risks materialize affect performance obligations us financial results may adversely affected manufacturing operations subject routine inspections regulatory agencies unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates delayed production marketed products interrupted anticipated revenues stock price may adversely affected may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials manufacture sell products unable purchase sufficient quantities materials find suitable alternative materials timely manner development efforts product candidates may delayed ability manufacture products could limited could limit ability generate revenues suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand could turn decrease revenues harm business addition deliveries materials suppliers interrupted reason may unable ship certain products commercial supply supply product candidates development clinical trials addition products materials utilize operations manufactured one facility may able replace timely manner commercially reasonable terms problems single suppliers depend including event disaster earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials could adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability conduct clinical trials product candidates manufacture sell products could impaired could adverse effect business imports countries products available lower prices unapproved generic counterfeit versions products could negative impact reputation business prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported resold countries lower price markets hiv hbv hcv products agreed make available substantially reduced prices certain low middleincome countries participating gilead access program reexported united states europe higher price markets revenues could adversely affected addition entered agreements generic drug manufacturers well licensing agreement medicines patent pool united nationsbacked public health organization allows generic drug manufacturers manufacture certain generic versions products distribution certain low middleincome countries generic versions products produced andor distributed agreements reexported united states europe higher price markets revenues could adversely affected european union required permit products purchased one eu member state sold another eu member state purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business additionally use diverted products could occur countries approved patients could source product outside legitimate supply chain therefore products may handled shipped stored inappropriately may affect efficacy product could harm patients brands commercial scientific reputation products also aware existence various buyers clubs around world promote personal importation generic versions hcv hiv products approved use countries imported result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances extent patients take unapproved generic versions one medications injured generic products brands commercial scientific reputation hcv hiv products could harmed third parties may illegally distribute sell counterfeit versions products meet rigorous quality standards manufacturing supply chain actively take actions discourage distribution sale counterfeits products around world including working local regulatory legal authorities enforce laws counterfeit drugs raising public awareness dangers counterfeit drugs promoting public policies hinder sale availability counterfeit drugs counterfeit drugs pose serious risk patient health safety may raise risk product recalls reputation business could suffer result counterfeit drugs sold brand names expensive litigation government investigations increased expenses may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings require significant management attention description litigation investigations disputerelated matters see note commitments contingencies notes consolidated financial statements included part ii item annual report see also may required pay significant damages royalty payments result ongoing litigation related yescarta biktarvy outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business reputation may face significant liability resulting products liability could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise claims exceed coverage financial condition adversely affected addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition description product liability matters see note commitments contingencies notes consolidated financial statements included part ii item annual report form k fail attract develop retain highly qualified personnel business operations may adversely affected future success depend large part continued ability attract develop retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms ability also depends well maintain strong workplace culture attractive employees particularly leadership transition currently experiencing additionally changes us immigration work authorization laws regulations could make difficult employees work transfer jurisdictions operations could impair ability attract retain qualified personnel unsuccessful recruitment development retention efforts fail maintain strong workplace culture business reputation may harmed recently made significant changes senior leadership team appointed daniel oday chairman chief executive officer andrew dickinson chief financial officer johanna mercier chief commercial officer merdad parsey chief medical officer brett pletcher executive vice president corporate affairs general counsel jyoti mehra executive vice president human resources christi shaw chief executive officer kite changes management key personnel may lead potential organizational realignments additional personnel changes may disrupt business adversely affect operations business disruptions natural manmade disasters may adversely affect revenues materially reduce earnings worldwide operations thirdparty manufacturers corporate partners could subject business interruptions stemming natural manmade disasters climate change terrorist attacks armed conflicts earthquakes hurricanes flooding fires actual threatened public health emergencies efforts taken third parties prevent mitigate disasters public safety power shutoffs facility shutdowns may uninsured inadequately insured corporate headquarters foster city santa monica location together house majority rd activities san dimas la verne oceanside el segundo manufacturing facilities located california seismically active region may carry adequate earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake dependent information technology systems infrastructure data may subject cyberattacks security breaches legal claims dependent upon information technology systems infrastructure data including kite konnect platform critical ensure chain identity chain custody yescarta multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion random attack likewise data privacy security breaches employees others pose risk sensitive data including intellectual property trade secrets personal information employees patients customers business partners may exposed unauthorized persons public cyberattacks increasing frequency sophistication intensity cyberattacks could include deployment harmful malware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture invested continue invest protection data information technology infrastructure assurance efforts efforts partners vendors prevent future service interruptions identify breaches systems interruptions breaches could adversely affect business operations andor cause loss critical sensitive information including personal information could result financial legal business reputational harm us addition insurance may sufficient type amount cover financial legal business reputational losses may result interruption breach systems regulators globally also imposing new data privacy security requirements including new greater monetary fines privacy violations example general data protection regulation gdpr became effective europe established regulations regarding handling personal data non compliance gdpr may result monetary penalties four percent worldwide revenue addition new domestic data privacy security laws california consumer privacy act ccpa became effective january others may passed similarly introduce requirements respect personal information noncompliance ccpa may result liability private actions subject statutorily defined damages event certain data breaches enforcement gdpr ccpa changes new laws regulations associated enhanced protection personal information including cases healthcare data personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate changes effective income tax rate could reduce earnings subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws predict form timing potential legislative regulatory changes could material adverse impact results operations example united states enacted significant tax reform certain provisions new law complex continue significantly affect us addition significant judgment required determining worldwide provision income taxes various factors may favorable unfavorable effects income tax rate including limited portion nontax deductible annual branded prescription drug fee accounting stock options sharebased awards mergers acquisitions future levels rd spending ability maintain manufacturing operational activities irish facilities changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated results operations income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period assurance continue pay dividends repurchase stock board directors authorized dividend program intend pay quarterly dividends per share subject quarterly declarations board directors first quarter board directors also approved repurchase billion common stock program billion available repurchase december first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions future declarations amount timing dividends andor amount timing stock repurchases subject capital availability determinations board directors cash dividends andor stock repurchases best interest stockholders compliance respective laws agreements applicable declaration payment cash dividends repurchase stock ability pay dividends andor repurchase stock depend upon among factors cash balances potential future capital requirements strategic transactions including acquisitions debt service requirements results operations financial condition factors beyond control board directors may deem relevant reduction elimination dividend payments dividend program andor stock repurchases could negative effect stock price item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative certain rd activities also rd facilities emeryville oceanside santa monica california gaithersburg maryland seattle washington edmonton canada amsterdam netherlands principal manufacturing facilities el segundo la verne oceanside san dimas california edmonton canada cork ireland hoofddorp netherlands information manufacturing facilities see item business manufacturing facilities global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings please see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report incorporated herein reference item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild february approximately stockholders record common stock performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested equity compensation plan information following table provides certain information respect equity compensation plans effect december millions except per share amounts number common shares remaining available future issuance equity number common shares weightedaverage compensation plans issued upon exercise exercise price excluding securities outstanding options warrants outstanding options reflected column rights warrants rights plan category b c equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total take account million restricted stock units performance share awards units phantom shares exercise price granted equity incentive plan employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable issuer purchases equity securities first quarter board directors authorized billion share repurchase program program repurchases may made open market privately negotiated transactions repurchased retired million shares common stock billion open market transactions program table summarizes stock repurchase activity three months ended december thousands except per share amounts maximum fair total number value shares total number average shares purchased may yet shares price paid part publicly purchased purchased per share announced program program october october november november december december total difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock unit awards order satisfy applicable tax withholding obligations first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions item selected financial data gilead sciences inc selected consolidated financial data millions except per share amounts year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted cash dividends declared per share december consolidated balance sheet data cash cash equivalents marketable debt securities working capital total assets longterm obligations longterm debt including current portion retained earnings total stockholders equity see managements discussion analysis financial condition results operations included item annual report description results operations adopted accounting standards update topic revenue contracts customers using modified retrospective method results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic revenue recognition december recorded deferred tax benefit billion related intangible asset transfers foreign subsidiary ireland united states recorded deferred tax charge million related transfer acquired intangible assets foreign subsidiary united states december recorded estimated billion net charge related enactment tax cuts jobs act tax reform tax reform also lowered corporate tax rate united states effective tax years beginning december see note income taxes notes consolidated financial statements included item annual report additional details investments equity securities equity method investments elected fair value method accounting recorded fair market value fair value readily determinable beginning january unrealized gains losses included income expense net consolidated statements income periods presented prior january unrealized gains losses included accumulated comprehensive income separate component stockholders equity repaid billion principal amount senior unsecured notes maturity repaid billion principal amount senior unsecured notes maturity repaid billion term loans borrowed connection acquisition kite pharma inc connection acquisition kite pharma inc issued billion aggregate principal amount senior unsecured notes borrowed billion aggregate principal amount term loan facility credit agreement billion repaid issued billion principal amount senior unsecured notes repaid million principal balance convertible senior notes million principal balance senior unsecured notes maturity issued billion principal amount senior unsecured notes repaid million principal balance convertible senior notes maturity adopted accounting standards update topic leases requires lessees recognize rightofuse assets lease liabilities operating leases lease term greater one year adopted topic using modified retrospective method results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic leases see note organization summary significant accounting policies note leases notes consolidated financial statements included item annual report information item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures part item risk factors additional information related comparison results operations years included item managements discussion analysis financial condition results operations filed sec incorporated reference annual report consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include viral diseases inflammatory fibrotic diseases oncology seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy descovy prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements business highlights financial performance solid growth across hiv franchise continued drive results took several significant steps position us future growth including important research development rd collaboration introduction new corporate strategy hiring key members executive leadership team developed new corporate strategy guide work seek drive growth next decade ambitious goal launching new transformative therapies next years continued make progress pipeline currently clinicalstage programs programs either registrational label enabling studies programs four already received breakthrough therapy designation us food drug administration fda achieved sales billion across hiv franchise increase reaching another alltime high continued revenue growth hiv products driven demand biktarvy increase number individuals taking products preexposure prophylaxis prep end biktarvy available major markets united states approximately individuals prep receiving descovy entered transformative rd collaboration galapagos nv galapagos july building existing partnership effectively enabling us double rd footprint accelerate development novel treatments inflammatory fibrotic diseases submitted regulatory filing filgotinib fda compound priority review rheumatoid arthritis ra also submitted filgotinib approval europe japan actively prepared competitive launches three regions galapagos continued advance phase study glpg treatment idiopathic pulmonary fibrosis regard nonalcoholic steatohepatitis nash stellar atlas studies failed reach primary endpoints continued work understand results determine appropriate next steps therapies including potential combination therapeutic approaches cell therapy kite gilead company kite submitted ktex regulatory approval united states europe treatment relapsed refractory mantle cell lymphoma mcl approved kite first company two cell therapies market also continued demonstrate efficacy yescarta data shared end showed approximately half patients treated yescarta refractory large bcell lymphoma still alive three years following treatment zuma study confirming yescartas benefitrisk profile addition cell therapy continued grow research portfolio immunooncology business also expanded geographically including china eight products approved since four products vemlidy epclusa harvoni genvoya listed national reimbursement drug list effective january continued advance product pipeline across therapeutic areas goal delivering bestinclass drugs potential improve lives patients serious illnesses key corporate product pipeline updates included viral diseases licensing collaboration agreements rockefeller university novartis ag lyndra therapeutics inc approval vosevi biktarvy china national medical products administration approval prep indication descovy fda approval biktarvy epclusa japans ministry health labour welfare mhlw inflammatory fibrotic diseases collaborations kyverna therapeutics inc glympse bio inc renown institute health innovation goldfinch bio inc insitro inc novo nordisk yuhan corporation agreement eisai co ltd distribution copromotion filgotinib japan pending regulatory approval japans mhlw treatment ra submission new drug application nda priority review fda submission nda japans mhlw filgotinib topline results phase atlas study combination monotherapy investigational treatments patients bridging fibrosis f compensated cirrhosis f due nash study meet primary endpoint continued analyze atlas data determine appropriate next steps therapies collaboration galapagos equity investment galapagos gain access galapagos current future product portfolio see note collaborative arrangements notes consolidated financial statements included item annual report additional information european medicines agencys validation marketing authorization application filgotinib application evaluation agency oncology fdas acceptance biologics license application granting priority review designation ktex treatment adult patients relapsed refractory mcl european medicines agencys validation marketing authorization application ktex application evaluation agency collaborations carna biosciences inc nurix therapeutics inc humanigen inc kiniksa pharmaceuticals ltd leadership changes put place diverse highly experienced leadership team senior leadership changes included appointment daniel p oday chairman chief executive officer andrew dickinson executive vice president chief financial officer merdad v parsey chief medical officer christi l shaw chief executive officer kite johanna mercier chief commercial officer departures john g mchutchison chief scientific officer head research development gregg h alton chief patient officer katie l watson executive vice president human resources planned retirement robin l washington role executive vice president chief financial officer donation us centers disease control prevention million bottles truvada descovy annually uninsured americans risk hiv financial highlights total revenues increased billion total product sales increased billion compared billion billion respectively primarily due higher sales hiv products partially offset lower sales ranexa letairis hcv products united states product sales billion compared billion europe product sales billion compared billion product sales international locations billion compared billion cost goods sold decreased billion compared billion primarily due million lower royalty expenses lower amortization expenses related intangible assets associated ranexa partially offset higher inventory writedowns recorded write downs million million respectively slow moving excess raw material work process inventory primarily due lower longterm demand hcv products rd expenses increased billion compared billion primarily due upfront collaboration licensing expenses billion related collaboration galapagos well higher personnel costs largely support cell therapy business partially offset lower stockbased compensation expense recorded impairment charges million million respectively related inprocess rd iprd intangible assets acquired connection acquisition kite pharma inc selling general administrative sga expenses increased billion compared billion primarily due promotional expenses united states expenses associated expansion business japan china partially offset lower stockbased compensation expense net income attributable gilead changed billion per diluted share compared billion per diluted share primarily due pretax upfront collaboration licensing expenses billion related collaboration galapagos partially offset net favorable fluctuation tax effects intraentity intangible asset transfers different tax jurisdictions increase net unrealized gains equity securities yearoveryear diluted earnings per share favorably impacted stock repurchase activities december billion cash cash equivalents marketable debt securities compared billion december generated billion operating cash flow paid billion connection collaboration equity investments galapagos classified cash flows investing activities also repaid billion principal amount debt paid cash dividends billion utilized billion repurchases common stock strategy outlook focus create possibilities patients scientific breakthroughs innovation leveraging pillars durable core business existing pipeline opportunities strategy drive additional growth strategy includes ambitions priorities enable us achieve ambitions strategic ambitions define success looks like next decade summarized bring transformative therapies patients ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priorities reflect deliver ambitions expand internal external innovation ii strengthen portfolio strategy decision making iii increase patient benefit access iv continue evolve culture expect underlying growth base business expected offset fullyear impact cardiopulmonary products loss exclusivity occurred initial generic version truvada united states late also continue invest support growth biktarvy descovy prep launch preparation competitive launches filgotinib ra united states japan europe continued investments pipeline cell therapy external partnerships overall plan guided newly established corporate strategy provides focus guides resource capital allocation priorities expect data readouts including filgotinib ulcerative colitis ktex acute lymphoblastic leukemia axicabtagene ciloleucel cd indolent bcell nonhodgkin lymphoma inhl second line diffuse large bcell lymphoma glpg osteoarthritis augment product pipeline continue pursue opportunities collaborations partnerships strategic investments fit longterm strategic plan progress initiatives subject number uncertainties including limited possibility unfavorable results new ongoing clinical trials continuation uncertain global macroeconomic environment additional pricing pressures payers competitors slower anticipated growth hiv products increase discounts chargebacks rebates due ongoing contracts future negotiations commercial government payers market share price erosion caused introduction generic versions products containing tenofovir disoproxil fumarate tdf outside united states viread letairis ranexa united states inaccuracies hcv patient start estimates potential amendments affordable care act government action could effect lowering prices largerthan anticipated shift payer mix highly discounted payer segment volatility foreign currency exchange rates results operations total revenues following table summarizes periodoverperiod changes revenues millions except percentages change change revenues product sales royalty contract revenues total revenues product sales compared total product sales increased billion compared billion primarily due higher sales hiv products partially offset lower sales ranexa letairis hcv products hiv product sales increased billion compared billion primarily due higher sales volume result continued uptake biktarvy increase partially offset decreases sales volumes genvoya truvada emtricitabine ftctdfbased products lower average net selling price hcv product sales decreased billion compared billion primarily due lower average net selling price including decline us medicare prices yescarta sales increased million compared million primarily due higher number therapies provided patients continued expansion europe product sales include vemlidy viread letairis ranexa zydelig ambisome cayston decreased billion compared billion primarily due expected decline sales ranexa letairis entry generic versions united states early total product sales generated outside united states faced exposure movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges immaterial impact product sales based comparison using foreign currency exchange rates record product sales net estimated government rebates chargebacks cash discounts prompt payment distributor fees related costs deductions generally referred grosstonet deductions totaled billion gross product sales compared billion gross product sales billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs product sales united states increased billion compared billion primarily due higher sales hiv products partially offset lower sales ranexa letairis following entry generic versions lower sales hcv products increase sales hiv products primarily due continued uptake biktarvy increase number individuals taking prep partially offset decreases sales volumes hiv products including genvoya atripla stribild decrease sales hcv products primarily due lower average net selling price including decline us medicare prices product sales europe decreased billion compared billion primarily due lower sales hcv products broader availability generic versions truvada atripla decrease sales hcv products primarily due lower patient starts lower average net selling price decrease partially offset continued uptake biktarvy odefsey yescarta favorable net adjustments government rebates related sales made prior years product sales international locations increased billion compared billion primarily due higher hiv product sales japan result acquiring rights certain products hiv portfolio japan effective january higher hcv product sales japan due launch epclusa following table summarizes periodoverperiod changes product sales millions except percentages change change atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv ambisome ledipasvirsofosbuvir letairis ranexa sofosbuvirvelpatasvir vemlidy viread vosevi yescarta zydelig total product sales percentage greater includes emtriva tybost represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland uc amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes cayston hepsera sovaldi following additional discussion sales hiv hcv products descovy ftctafbased products biktarvy descovy genvoya odefsey revenue share symtuza following table summarizes periodoverperiod changes sales descovy ftctafbased products millions except percentages change change us europe locations total total product sales hiv product sales descovy ftctafbased product sales increased major markets compared increase united states europe primarily due higher demand shift product mix toward biktarvy increase international locations primarily due higher product sales japan result acquiring rights certain products hiv portfolio japan effective january truvada ftctdfbased products atripla compleraeviplera stribild truvada following table summarizes periodoverperiod changes sales truvada ftctdfbased products millions except percentages change change us europe locations total total product sales truvada ftctdfbased product sales decreased united states europe compared decrease us sales primarily due lower sales volume result patients switching newer regimens containing ftctaf partially offset increased usage truvada prep decrease europe sales primarily due lower sales volumes truvada atripla result broader availability generic versions patients switching newer regimens containing ftctaf expect decline sales truvada united states patients switch descovy prep truvada prep expected entry generic versions late hcv products epclusa harvoni sovaldi vosevi authorized generics epclusa harvoni following table summarizes periodoverperiod changes sales hcv products millions except percentages change change us europe locations total total product sales decrease hcv product sales united states compared primarily due lower average net selling price including decline us medicare prices decrease hcv product sales europe compared primarily due lower patient starts lower average net selling price partially offset favorable net adjustments government rebates discounts related sales made prior years decrease hcv product sales international locations compared primarily due lower sales sovaldi partially offset higher sales epclusa cost goods sold product gross margin following table summarizes periodoverperiod changes product sales cost goods sold product gross margin millions except percentages change change total product sales cost goods sold product gross margin cost goods sold decreased million compared primarily due lower royalty expenses lower amortization expense related intangible assets associated ranexa fully amortized first quarter partially offset higher inventory writedowns recorded inventory writedowns million million related slow moving excess raw material work process inventory primarily due lower longterm demand hcv products recorded inventory writedowns million million related excess raw materials primarily due sustained decrease demand harvoni result shift market harvoni epclusa royalty expenses decreased million compared primarily due lower sales atripla ranexa letairis products containing elvitegravir research development expenses following table summarizes periodoverperiod changes rd expenses millions except percentages change change rd expenses rd expenses consist primarily clinical studies performed contract research organizations materials supplies payments collaborative arrangements including upfront milestone payments licenses fees well expense reimbursements collaboration partners iprd impairment charges personnel costs including salaries benefits stockbased compensation expense overhead allocations consisting various support infrastructure costs track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability technical regulatory successful development market potential available human capital resources considerations continually review rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities believe best support longterm growth business following table provides breakout rd expenses major cost type millions except percentages change change upfront collaboration licensing expenses personnel infrastructure expenses clinical studies outside services iprd impairment charges stockbased compensation expenses total percentage greater rd expenses increased billion compared primarily due billion upfront collaboration licensing expenses related collaboration galapagos well higher personnel costs largely support cell therapy business increased investment research projects partially offset lower stockbased compensation expense recorded impairment charge million related iprd intangible assets acquired connection acquisition kite pharma inc primarily treatment indolent nonhodgkin lymphoma largely driven changes estimated market opportunities new therapies combinations existing therapies approved recorded impairment charge million related iprd intangible assets kite program antib cell maturation antigen evaluated treatment multiple myeloma due discontinuance stockbased compensation expense decreased million compared primarily due impact stockbased compensation expense associated acquisition kite pharma inc selling general administrative expenses following table summarizes periodoverperiod changes sga expenses millions except percentages change change sga expenses sga expenses relate sales marketing finance human resources legal administrative activities expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales truedup upon receipt invoices internal revenue service sga expenses increased million compared primarily due higher promotional expenses united states expenses associated expansion business japan china partially offset lower stockbased compensation expense stockbased compensation expense decreased million compared primarily due impact stockbased compensation expense associated acquisition kite pharma inc bpd fee expenses million million million respectively bpd fee expenses taxdeductible income expense net following table summarizes periodoverperiod changes income expense net millions except percentages change change income expense net change income expense net compared primarily due higher net unrealized gains billion changes fair value equity securities largely relating equity investments galapagos starting january recorded unrealized gains losses changes fair value marketable equity securities income expense net consolidated statements income result adoption accounting standards update financial instruments overall recognition measurement financial assets financial liabilities provision income taxes following table summarizes periodoverperiod changes provision income taxes millions except percentages change change effective tax rate provision income taxes decrease effective tax rate provision income taxes compared primarily due billion deferred tax benefit related intangible asset transfers foreign subsidiary ireland united states effective tax rate included million deferred tax charge resulting transfer acquired intangible assets foreign subsidiary united states decrease effective tax rate provision income taxes compared primarily due billion net tax charge reduction us corporate tax rate result enactment tax cuts jobs act tax reform december effective tax rate decreased due million tax benefit recorded related settlement tax examinations offset million deferred tax charge discussed changes geographic mix earnings tax global intangible lowtaxed income enacted part tax reform see note income taxes notes consolidated financial statements included item annual report additional details tax reform liquidity capital resources following table summarizes cash cash equivalents marketable debt securities working capital december millions cash cash equivalents marketable debt securities working capital cash cash equivalents marketable debt securities cash cash equivalents marketable debt securities decreased billion compared december generated billion operating cash flow paid billion connection collaboration equity investments galapagos repaid billion debt paid cash dividends billion repurchased million shares common stock billion open market transactions working capital working capital decreased billion compared december primarily due use cash noted heading cash cash equivalents marketable debt securities cash flows following table summarizes cash flow activities millions cash provided used operating activities investing activities financing activities cash provided operating activities cash provided operating activities represents cash receipts disbursements related activities investing financing activities operating cash flow derived adjusting net income noncash items changes operating assets liabilities cash provided operating activities increased million billion compared primarily due lower tax payments partially offset lower collections accounts receivable collection receivable bristolmyers squibb company following termination collaboration pursuant terms existing agreements tax payments made included million payment related first annual installment tax reform transition tax million deemed early payment tax reform transition tax million settlement tax examination starting upfront milestone payments related collaborative arrangements classified cash flows investing activities consolidated statements cash flows comparative prior year amounts material reclassified investing activities operating activities cash provided used investing activities cash provided used investing activities primarily consists purchases sales maturities marketable debt securities capital expenditures front milestone payments related collaborative arrangements purchases equity securities investments cash used investing activities billion compared cash provided investing activities billion change cash provided used investing activities primarily due higher purchases marketable debt securities billion payments made connection collaboration equity investments galapagos partially offset higher proceeds sales marketable debt securities higher purchases marketable debt securities result shift investment strategy investing longer dated securities compared addition paid japan tobacco inc million connection acquiring rights market distribute certain hiv products japan cash provided investing activities billion compared cash used investing activities billion change cash provided used investing activities primarily due higher proceeds maturities marketable debt securities lower purchases marketable debt securities partially offset lower proceeds sales marketable debt securities addition billion cash used acquire kite pharma inc whereas cash used business combinations cash provided used financing activities cash used financing activities decreased billion billion compared primarily due billion lower repayments debt billion lower repurchases common stock cash used financing activities billion compared cash provided financing activities billion change cash provided used financing activities primarily due higher repayment debt repurchases common stock addition billion net proceeds debt issuances partially fund acquisition kite pharma inc whereas debt issued debt credit facilities repaid maturity billion billion principal amount senior unsecured notes respectively addition repaid billion borrowed term loan facility credit agreement time term loan facility credit agreement terminated february repaid maturity million principal amount senior unsecured notes december amounts outstanding billion fiveyear revolving credit facility maturing may required comply certain covenants notes indentures december violation covenants summary borrowings various financing arrangements included note debt credit facilities notes consolidated financial statements included item annual report capital return program details stock repurchase programs dividends included note stockholders equity notes consolidated financial statements included item annual report stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april repurchases program million million shares common stock billion billion respectively december remaining authorized repurchase amount program billion first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions dividends declared paid quarterly cash dividends aggregate amount billion per share common stock billion per share common stock respectively february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors capital resources believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements included item annual report prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party upon recognition revenue product sales provisions made various forms variable consideration include government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate variable consideration included net sales price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved government rebates chargebacks represent majority variable consideration require complex significant judgment management estimates assessed period updated reflect current information government rebates chargebacks government rebates chargebacks include amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance program rebates chargebacks veterans administration public health service chargebacks rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price allowances government rebates chargebacks estimated based products sold historical payer mix available pertinent third party industry information estimated patient population known market events trends us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration available new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future payer mix programs believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates historically actual government rebates chargebacks claimed prior periods varied less estimates government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets totaled million million december respectively government rebates payable third party payers healthcare providers recorded accrued government rebates consolidated balance sheets totaled billion billion december respectively following table summarizes consolidated activities ending balances government rebates chargebacks accounts balance decreaseincrease balance end millions beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total legal contingencies party various legal actions significant described note commitments contingencies legal proceedings notes consolidated financial statements included item annual report possible determine outcome matters recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss significant judgment required determination probability determination whether exposure reasonably estimable inherent uncertainty unpredictability related matters accruals based believe best information available time assessment including legal facts circumstances case status proceedings applicable law views legal counsel upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes material accruals consolidated balance sheets matters december valuation intangible assets acquired expect continue acquire intangible assets acquisition consolidation variable interest entities identifiable intangible assets measured respective fair values acquisition date may subject revision within measurement period may one year acquisition date fair values assets generally determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability technical regulatory success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired based upon reasonable estimates assumptions given facts circumstances related valuation dates intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived amortized based respective estimated useful lives point time primarily straightline basis intangible assets reviewed impairment annual basis well annual tests become aware events changes would indicate likely fair values intangible assets andor iprd projects respective carrying amounts performing quantitative impairment assessments calculate fair value using discounted cash flow models require significant estimates assumptions similar methodology determining acquisition date fair value intangible assets described carrying value intangible asset exceeds fair value intangible asset writtendown fair value significant judgment employed determining estimates assumptions changes estimates assumptions could significant impact results operations given period example recognized million impairment charge related iprd projects primarily treatment indolent nonhodgkin lymphoma due changes estimated market opportunities often major risks uncertainties associated iprd projects required obtain regulatory approvals order able market products approvals require completing clinical trials demonstrate product candidate safe effective consequently eventual realized value acquired iprd project may vary fair value date acquisition iprd impairment charges may occur future periods could material adverse effect results operations example concluded kite program acquired connection acquisition kite pharma inc justify efforts based totality clinical data gathered discontinued program result carrying value iprd relating kite program written zero recorded impairment charge million see note intangible assets notes consolidated financial statements included item annual report additional information impairment charges related indefinitelived iprd intangible assets provision income taxes estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws example united states enacted significant tax reform certain provisions new law continue significantly affect us predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period see note income taxes notes consolidated financial statements included item annual report additional information balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations represent future cash commitments related significant enforceable legally binding obligations certain purchase obligations likely continue regardless fact may cancelable expected timing payment amounts presented estimated based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts following table summarizes aggregate maturities contractual obligations december payments due period millions total thereafter debt operating lease obligations purchase obligations transition tax payable total debt consists senior unsecured notes includes principal future interest payments interest payments fixed rate senior unsecured notes incurred calculated based terms related notes see note debt credit facilities notes consolidated financial statements included item annual report additional information see note leases notes consolidated financial statements included item annual report additional information amounts primarily relate capital commitments active pharmaceutical ingredients api minimum purchase commitments certain inventoryrelated items advertising rd commitments significant rd commitments related clinical studies performed contract research organizations cros excluded table material cro contracts cancelable us addition table reflect approximately million additional minimum purchase commitments resulting api contract amended january connection tax reform recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period amounts included table represent remaining federal income tax payable december december longterm income taxes payable includes unrecognized tax benefits interest penalties totaling billion due high degree uncertainty timing future cash settlement events could extinguish unrecognized tax benefits unable estimate period cash settlement therefore excluded unrecognized tax benefits committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally contingent upon certain future events including achievement certain developmental regulatory commercial milestones achievement events neither probable reasonably estimable potential payments recorded consolidated balance sheets included table recent accounting pronouncements information required item included note organization summary significant accounting policies notes consolidated financial statements included item annual report item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks market price reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations countries worldwide result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december december would resulted reduction fair value contracts approximately million million respectively date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale debt securities fixed rate longterm debt create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december expected maturity millions except total fair percentages thereafter total value assets availableforsale debt securities average interest rate liabilities fixed rate long term debt including current portion average interest rate amounts represent principal balances addition fixed rate longterm debt billion fiveyear revolving credit facility matures may amounts outstanding five year revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information market price risk hold shares common stock certain publicly traded biotechnology companies primarily connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings fair value equity securities approximately billion million december respectively changes fair value equity securities impacted volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increase decrease fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements selected quarterly financial information unaudited schedule ii valuation qualifying accounts report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate government commercial rebates description fully described note company estimates reductions revenues amounts payable payers healthcare matter providers united states various government commercial rebate programs period related sales occur rebates may vary product payer individual payer plans may known point sale estimated reductions revenue based products sold historical payer mix historical discount rates various estimated actual data adjusted current period expectations auditing companys estimated reductions revenue rebates complex involved significant judgment particularly assessing reasonableness estimated payer utilization discount rates applied sales period estimates rely heavily historical data adjusted changes utilization discount rates time addressed evaluated tested design operating effectiveness companys internal controls managements estimation matter review reductions revenue rebate programs including controls assess utilization rate discount rate assumptions audit also tested completeness accuracy data utilized controls accuracy calculations supporting managements estimates test managements estimation methodology determining utilization discount rates audit procedures included among others evaluating evidence contrary estimated amounts performing sensitivity analysis rates used estimates performing comparison actual payments related amounts accrued current prior year valuation inprocess research development intangible assets description december companys inprocess research development iprd intangible assets billion company matter recorded impairment charge million year discussed note intangible assets indefinite useful lives related purchased iprd projects measured respective fair values acquisition date considered indefinitelived completion abandonment associated rd efforts company tests indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts auditing impairment tests complex due significant judgment required estimating fair values iprd intangible assets particular fair value estimates sensitive significant assumptions eg discount rate projected research development costs probability technical success addressable patient population projected market share product profitability affected expected future market economic conditions addressed evaluated tested design operating effectiveness companys internal controls determination matter estimated fair value iprd intangible assets example tested controls managements review valuation models audit significant assumptions used develop fair value estimates indefinite lived intangible assets also tested managements controls validate data used fair value estimates complete accurate test estimated fair value companys iprd intangible assets audit procedures included among others evaluating companys use appropriate valuation methodologies assistance valuation specialist testing significant assumptions discussed testing completeness accuracy underlying data example compared significant assumptions current industry market economic trends historical results companys business guideline companies within industry relevant factors addition evaluate probability technical success considered phase development iprd projects companys history obtaining regulatory approval also performed sensitivity analysis significant assumptions evaluate change estimated fair values iprd intangible assets resulting changes assumptions ernst young llp served companys auditor since san jose california february gilead sciences inc consolidated balance sheets millions except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances respectively inventories prepaid current assets total current assets property plant equipment net longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income millions except per share amounts year ended december revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net loss income attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted see accompanying notes gilead sciences inc consolidated statements comprehensive income millions year ended december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt securities net unrealized gain net tax reclassifications net income net tax net change cash flow hedges net unrealized gain loss net tax reclassification net income net tax net change comprehensive income loss comprehensive income comprehensive loss income attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity millions except per share amounts gilead stockholders equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders shares amount capital income loss earnings interest equity balance december change noncontrolling interest net income comprehensive loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december change noncontrolling interest net income comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share cumulative effect adoption new accounting standards balance december net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share cumulative effect adoption new accounting standards note balance december see accompanying notes gilead sciences inc consolidated statements cash flows millions year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes net gains equity securities upfront milestone expense related collaborative arrangements inprocess research development impairment writedowns slow moving excess raw material work process inventory changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable debt securities proceeds sales marketable debt securities proceeds maturities marketable debt securities upfront milestone payments related collaborative arrangements purchases equity securities acquisitions net cash acquired capital expenditures net cash used provided investing activities financing activities proceeds debt financing net issuance costs proceeds issuances common stock repurchases common stock repayments debt obligations payment dividends net cash used provided financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include viral diseases inflammatory fibrotic diseases oncology seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy descovy prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig also sell distribute authorized generic versions epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties assess whether primary beneficiary variable interest entity vie inception arrangement reporting date assessment based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition january adopted accounting standards update revenue contracts customers topic using modified retrospective method topic supersedes revenue recognition requirements topic revenue recognition topic result changed accounting policies revenue recognition detailed policy elections practical expedients taken account shipping handling activities performed customer obtained control good fulfillment costs rather separate performance obligations expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects significant financing component product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party upon recognition revenue product sales provisions made various forms variable consideration include government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate variable consideration included net sales price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved payment terms customers generally range days variable consideration rebates chargebacks estimate reductions revenues amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance program rebates chargebacks veterans administration public health service rebates chargebacks well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans estimates based products sold historical payer mix available pertinent thirdparty industry information estimated patient population known market events trends us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration available new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future payer mix programs government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets government rebates payable third party payers healthcare providers recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return typically permit returns product damaged defective otherwise used received customer case product sold united states certain countries product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns historical industry information reporting return rates similar products contractual agreements intended limit amount inventory maintained wholesalers royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies payments collaborative arrangements including upfront milestone payments license option fees well expense reimbursements collaboration partners overhead allocations consisting various support infrastructure costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination selling general administrative expenses selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales expense costs advertising including promotional expenses incurred advertising expenses million million million years ended december respectively cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable nonmarketable securities marketable debt securities determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date marketable debt securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale debt securities excluded net income reported accumulated comprehensive income loss aoci separate component stockholders equity income expense net includes interest amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline marketable nonmarketable equity securities investments equity securities equity method investments recorded fair market value fair value readily determinable beginning january unrealized gains losses included income expense net consolidated statements income periods presented prior january unrealized gains losses included aoci separate component stockholders equity investments entities significant influence meet requirements consolidation elected fair value option use equity method accounting share underlying income loss entities reported income expense net consolidated statements income elected fair value option account equity investment galapagos nv galapagos significant influence believe fair value option best reflects underlying economics investment see note collaborative arrangements additional information equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer certain investments equity securities nonpublic companies accounted using equity method based ownership percentage factors indicate significant influence investee investments equity securities without readily determinable fair values investments nonpublic companies accounted using equity method accounting material periods presented investments equity securities recorded prepaid current assets longterm assets consolidated balance sheet regularly review securities indicators impairment concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment doubtful accounts estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices majority trade accounts receivable arises product sales united states europe japan date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slow moving excess otherwise unsaleable items obsolete slow moving excess unsaleable items observed alternate uses inventory record writedown net realizable value charge cost goods sold consolidated statements income determination net realizable value requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors considered including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term acquisitions account business combinations using acquisition method accounting requires assets acquired including inprocess research development iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess purchase price fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred determine net assets acquired meet definition business combination acquisition method accounting transaction accounted acquisition assets therefore goodwill recorded contingent consideration payments upon achievement various developmental regulatory commercial milestones generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date subsequent milestone payments charged expense consolidated statements income unless alternative future use goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets measured respective fair values acquisition date may subject revision within measurement period may one year acquisition date intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts amortize goodwill intangible assets indefinite useful lives test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events circumstances would indicate fair values assets carrying amounts development successfully completed generally occurs regulatory approval obtained associated assets deemed finitelived amortized respective estimated useful lives beginning point time intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances indicate carrying value assets may recoverable impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may indicate carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset carrying amount asset asset group asset asset group determined impaired excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component aoci within stockholders equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains losses material years ended december hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives designated part hedge transaction recorded period current earnings aoci changes fair value derivatives part hedge transaction recorded period current earnings assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations record liabilities related unrecognized tax benefits accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period elected account tax global intangible lowtaxed income gilti enacted part tax cuts jobs act tax reform component tax expense period tax incurred period cost method presentation cash flows starting upfront milestone payments related collaborative arrangements classified cash flows investing activities consolidated statements cash flows comparative prior year amounts material reclassified investing activities operating activities recently adopted accounting pronouncements february financial accounting standards board fasb issued accounting standards update leases asu subsequently issued supplemental adoption guidance clarification collectively topic topic amends number aspects lease accounting including requiring lessees recognize rightofuse assets lease liabilities operating leases lease term greater one year topic supersedes topic leases january adopted topic using modified retrospective method results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic elected package practical expedients permitted transition guidance within topic allowed us carry forward historical lease classification retain initial direct costs leases existed prior adoption standard reassess whether contracts entered prior adoption leases also elected account lease nonlease components lease agreements single lease component determining lease assets liabilities addition elected recognize rightofuse assets liabilities leases lease terms one year less upon adoption topic recorded million rightofuse assets within longterm assets million operating lease liabilities classified primarily within longterm obligations consolidated balance sheet january adoption material impact consolidated statements operations consolidated statements cash flows see note leases additional information recently issued accounting pronouncements yet adopted june fasb issued accounting standards update financial instrumentscredit losses measurement credit losses financial instruments asu asu requires measurement recognition expected credit losses financial assets april fasb issued clarification asu within asu codification improvements topic financial instrumentscredit losses topic derivatives hedging topic financial instruments guidance become effective us beginning first quarter must adopted using modified retrospective approach certain exceptions expect adoption standards material impact consolidated financial statements november fasb issued accounting standards update collaborative arrangements topic clarifying interaction topic topic asu asu clarifies certain transactions participants collaborative arrangement accounted asc counterparty customer addition update precludes entity presenting consideration transaction collaborative arrangement revenue counterparty customer transaction guidance become effective us beginning first quarter applied retrospectively january initially adopted topic expect adoption standard material impact consolidated financial statements revenues disaggregation revenues following table disaggregates product sales product geographic region disaggregates royalty contract revenues geographic region millions year ended december year ended december year ended december us europe international total us europe international total us europe international total product sales atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza ambisome ledipasvirsofosbuvir letairis ranexa sofosbuvirvelpatasvir vemlidy viread vosevi yescarta zydelig total product sales royalty contract revenues total revenues includes emtriva tybost represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland uc janssen amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes cayston hepsera sovaldi information year ended december adjusted accordance modified retrospective adoption topic continues reported accordance historical accounting topic revenues recognized performance obligations satisfied prior periods revenues recognized performance obligations satisfied prior years related royalties licenses intellectual property million million years ended december respectively changes estimates variable consideration related sales made prior years resulted million increase million decrease revenues years ended december respectively contract balances contract assets consist unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation totaled million million december respectively contract liabilities material december fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist primarily cash cash equivalents marketable debt securities accounts receivable foreign currency exchange contracts equity securities accounts payable shortterm longterm debt cash cash equivalents marketable debt securities certain equity securities foreign currency exchange contracts reported respective fair values consolidated balance sheets equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer shortterm longterm debt reported amortized costs consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy millions december december level level level total level level level total assets availableforsale debt securities us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities equity securities equity investment galapagos money market funds publicly traded equity securities deferred compensation plan foreign currency derivative contracts total liabilities deferred compensation plan foreign currency derivative contracts total changes fair value equity securities resulted net unrealized gains billion million years ended december respectively included income expense net consolidated statements income following table summarizes classification equity investment galapagos consolidated balance sheets millions december december prepaid current assets longterm assets total see note collaborative arrangements additional information equity investment galapagos following table summarizes classification equity securities consolidated balance sheets millions december december cash cash equivalents prepaid current assets longterm assets total availableforsale debt securities classified cash equivalents shortterm marketable securities longterm marketable securities consolidated balance sheets see note availableforsale debt securities additional information level inputs estimate fair values level instruments taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates london interbank offered rates libor swap rates inputs applicable observable commonly quoted intervals total estimated fair values shortterm longterm debt determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs december assets liabilities measured using level inputs recurring basis contingent consideration liabilities material fair values acquired iprd assets based probabilityadjusted discounted cash flow calculations using level fair value measurements inputs including estimated revenues costs probability technical regulatory success discount rates amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts fourth quarter recognized impairment charge million associated iprd intangible assets acquired connection acquisition kite pharma inc kite primarily treatment indolent b cell nonhodgkin lymphoma inhl fourth quarter recognized impairment charge million write zero carrying value kite program antib cell maturation antigen evaluated treatment multiple myeloma see note acquisitions note intangible assets additional information policy recognize transfers level classification actual date event change circumstances caused transfer transfers level level level periods presented availableforsale debt securities following table summarizes availableforsale debt securities millions december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage asset backed securities total following table summarizes classification availableforsale debt securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable securities longterm marketable securities total following table summarizes availableforsale debt securities contractual maturity millions december amortized cost fair value within one year one year five years five years total following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired millions less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december corporate debt securities december us treasury securities us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total held total positions unrealized loss position december respectively based review securities believe otherthantemporary impairments december intend sell securities believe required sell securities recovery amortized cost basis gross realized gains gross realized losses availableforsale debt securities material years ended december derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities entities denominated non functional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturities months less upon executing hedging contract quarterly thereafter assess hedge effectiveness using regression analysis unrealized gains losses aoci reclassified product sales respective hedged transactions affect earnings majority gains losses related hedged forecasted transactions reported aoci december expected reclassified product sales within months cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding totaling billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts gross basis following table summarizes classification fair values derivative instruments consolidated balance sheets millions december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated financial statements millions year ended december derivatives designated hedges gain loss recognized aoci gain loss reclassified aoci product sales gain recognized income expense net derivatives designated hedges gain loss recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income discontinuance cash flow hedges years presented december held foreign currency exchange contracts following table summarizes potential effect offsetting derivatives type financial instrument consolidated balance sheets millions gross amounts offset consolidated balance sheets gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheets balance sheets instruments receivedpledged legal offset december derivative assets derivative liabilities december derivative assets derivative liabilities acquisitions kite pharma inc october acquisition date completed tender offer outstanding common stock kite per share cash result kite became whollyowned subsidiary acquisition kite helps establish foundation improving treatment hematological malignancies solid tumors consideration transferred acquisition million consisting million cash outstanding kite common stockholders million cash payment vested equity award holders million warrant holders million representing portion replaced stockbased awards attributable precombination period addition million excluded consideration transferred representing portion replaced stock based awards attributable post combination period replacement awards expected recognized december unrecognized compensation cost related replacement awards material acquisition kite accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed recognized fair value acquisition date determination estimated fair value requires us make significant estimates assumptions recorded million reduction goodwill primarily due revision deferred income taxes result finalization kites preacquisition federal income tax return fair value estimates assets acquired liabilities assumed completed following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred millions cash cash equivalents identifiable intangible assets indefinitelived intangible assets iprd outlicense acquired deferred income taxes assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily related iprd axicabtagene ciloleucel kite program ktex formerly ktec evaluated treatment acute lymphoblastic leukemia estimated aggregate fair value million acquisition date intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts october axicabtagene ciloleucel known commercially yescarta approved fda treatment adult patients relapsed refractory diffuse large bcell lymphoma dlbcl two lines systemic therapy upon fda approval yescarta million purchased iprd reclassified finitelived intangible asset amortized estimated useful life years using straightline method recognized impairment charge million primarily related axicabtagene ciloleucel treatment inhl recognized impairment charge million write zero carrying value kite program see note intangible assets additional information additionally acquired outlicensing arrangement daiichi sankyo company limited estimated fair value million acquisition date definitelived intangible asset amortized estimated useful life years straightline basis fair value determined estimating probabilityweighted net cash flows attributable outlicense discounted present value using discount rate represents estimated rate market participants would use value intangible asset goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed represents future economic benefits arising assets acquired could individually identified separately recognized none goodwill deductible income tax purposes cell design labs inc december acquired issued outstanding stock cell design labs inc privately held company cell design labs addition approximately shares cell design labs obtained acquisition kite acquisition gained new technology platforms enhance rd efforts cellular therapy cash consideration totaled million net acquired cash additionally shareholders cell design labs us eligible receive contingent development regulatory milestonebased payments million equity interest cell design labs carrying value million transaction accounted asset acquisition result million expensed acquired iprd within research development expenses consolidated statements income inventories following table summarizes inventories millions december raw materials work process finished goods total reported inventories longterm assets total amounts reported longterm assets primarily consisted raw materials december year ended december recorded inventory writedowns million million related slow moving excess raw material work progress inventory primarily due lower longterm demand hepatitis c virus hcv products year ended december recorded inventory writedowns million million related excess raw materials primarily due sustained decrease demand harvoni inventory writedowns recorded year ended december material property plant equipment following table summarizes property plant equipment millions december land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total office computer equipment includes capitalized software unamortized capitalized software costs consolidated balance sheets million million december respectively capitalized interest construction inprogress included property plant equipment interest capitalized material intangible assets following table summarizes intangible assets net millions december december gross foreign currency gross foreign currency carrying accumulated translation net carrying carrying accumulated translation net carrying amount amortization adjustment amount amount amortization adjustment amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total finitelived assets indefinitelived assets iprd total intangible assets aggregate amortization expense related finitelived intangible assets billion billion million years ended december respectively primarily included cost goods sold consolidated statements income amounts capitalized iprd subject impairment testing completion abandonment associated rd efforts fourth quarter performed quantitative impairment testing iprd intangible assets using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar profile represents rate market participants would use value intangible assets discounted cash flow models used valuing intangible assets also require use level fair value measurements inputs including estimated revenues costs probability technical regulatory success comparison assessment used lower estimated revenues due changes estimated market opportunities new therapies combinations existing therapies approved lower estimated revenues reduced fair value iprd intangible assets primarily related axicabtagene ciloleucel treatment inhl carrying value resulting recognition impairment charge million recorded within research development expenses consolidated statements income concluded kite program justify efforts based totality clinical data gathered discontinued program result carrying value iprd relating kite program written zero recorded impairment charge million within research development expenses consolidated statements income iprd impairment charges recorded following table summarizes estimated future amortization expense associated finitelived intangible assets december millions fiscal year amount thereafter total financial information accrued liabilities following table summarizes components accrued liabilities millions december compensation employee benefits income taxes payable accrued payment marketingrelated rights acquired japan tobacco inc accrued expenses total collaborative arrangements enter collaborative similar arrangements third parties development commercialization certain products product candidates arrangements involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities arrangements may include nonrefundable upfront payments payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements equity investments galapagos filgotinib collaboration closed license collaboration agreement galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications filgotinib agreement upon closing made upfront license fee payment equity investment galapagos subscribing million new ordinary shares galapagos price per share equity investment net issuance premium million terms filgotinib agreement amended exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib december galapagos eligible receive us potential future development regulatory milestonebased payments million salesbased milestone payments million plus tiered royalties global net sales ranging exception certain cocommercialization territories profits would shared equally cocommercialization territories uk germany france italy spain belgium netherlands luxembourg share global development costs filgotinib equally periods presented payments galapagos us development costs milestones material termination agreement may countrybycountry basis depend circumstances including expiration royalty term cocommercialization territories sale generic product material breach either party may also terminate entire agreement without cause following certain period global collaboration august closed option license collaboration agreement collaboration agreement subscription agreement subscription agreement galapagos pursuant parties entered global collaboration covers galapagos current future product portfolio filgotinib upon closing paid billion license option rights million new ordinary shares galapagos subscription price per share fair value billion included issuance discount million calculated based galapagos closing stock price date closing subscription agreement remaining billion payment recorded within research development expenses consolidated statements income pursuant subscription agreement issued warrants confer right subscribe time time number new shares issued galapagos sufficient bring number shares owned us issued outstanding shares time exercises fourth quarter exercised warrant subscribe million ordinary shares galapagos per share purchased shares open market aggregate fair value million brought number shares owned us million approximately shares issued outstanding equity investment galapagos classified longterm assets consolidated balance sheets subject contractual lockup provisions subject year standstill restricting ability acquire voting securities galapagos exceeding issued outstanding voting securities galapagos agreed without prior consent galapagos dispose equity securities galapagos prior second anniversary closing subscription agreement dispose equity securities galapagos thereafter fifth anniversary closing subscription agreement disposal would less issued outstanding voting securities galapagos subject certain exceptions termination events two designees appointed galapagos board directors elected fair value option account equity investment galapagos whereby investment marked market earnings reporting period based market price galapagos shares believe fair value option best reflects underlying economics investment see note fair value measurements additional information collaboration agreement exclusive license development commercialization glpg phase candidate idiopathic pulmonary fibrosis territories option participate development commercialization glpg phase b candidate osteoarthritis galapagos current future clinical programs entered clinical development first ten years collaboration subject extension certain circumstances may exercise option program receipt data package completed qualifying phase study program certain circumstances first phase study glpg receives marketing approval united states pay galapagos million well tiered royalties described exercise option glpg program pay million option exercise fee galapagos would eligible receive million development regulatory commercial milestones well tiered royalties described respect programs galapagos current future pipeline exercise option program pay million option exercise fee per program addition galapagos receive tiered royalties ranging net sales territories galapagos product optioned us including glpg glpg exercise option program parties share equally development costs mutually agreed commercialization costs incurred subsequent exercise option galapagos retains exclusive commercialization rights optioned programs european union uk iceland norway lichtenstein switzerland exclusive commercialization rights countries globally except glpg acquire us rights may terminate collaboration entirety programbyprogram countrybycountry basis advance notice well following customary termination events janssen compleraeviplera odefsey entered license collaboration agreement janssen sciences ireland uc janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside united states neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues including major markets sales products included product sales janssens shares revenues included cost goods sold consolidated statements income cost goods sold relating janssens shares million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide combination approved united states european union july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related cobicistat emtricitabine tenofovir alafenamide gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza see note revenues revenue recognized periods presented termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights paid royalty us based product sales japan agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales japan tobacco also marketed distributed certain products hiv portfolio japan paid royalty us based product sales received approval stribild genvoya elvitegravircontaining products respectively sales products included product sales royalties due japan tobacco based product sales included cost goods sold royalties due japan tobacco based product sales japan included royalty contract revenues consolidated statements income royalty expenses recognized million million million years ended december respectively royalty income recognized material periods presented effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january terms agreement paid japan tobacco million cash million paid upfront payment remaining million paid recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco remaining million recorded prepaid current assets consolidated balance sheets intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause gadeta july entered collaboration arrangement gadeta privatelyheld company based utrecht netherlands develop gamma delta cell receptor therapies various cancers financial terms provide rd funding collaboration gadeta eligible receive future payments upon achievement certain regulatory milestones addition made upfront purchase equity gadeta gadetas shareholders may acquire additional equity gadeta upon achievement certain rd milestones also exclusive option acquire remaining equity gadeta million adjusted closing cash transaction expenses closing indebtedness option exercisable discretion gadeta vie primary beneficiary power direct activities gadeta significantly impact economic performance result financial terms described upon initial consolidation gadeta recorded assets million primarily intangible assets related iprd million noncontrolling interest consolidated balance sheets gadeta meet definition business defined asc business combinations result goodwill recognized bristolmyers squibb company north america collaboration arrangement bristolmyers squibb company bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz united states canada combination sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated december terminated bmss participation collaboration following launch generic version sustiva us became sole owner joint venture bms permitted commercialize atripla united states canada entitled receive us certain fees based net sales atripla declining annual scale bms supplies sustiva us cost plus markup threeyear period may terminate supply agreement notice period bms notified us voluntary termination supply agreement years ended december recorded million million respectively fee expenses within cost goods sold consolidated statements income europe gilead sciences ireland uc whollyowned subsidiary bms collaboration agreement sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory parties also formed limited liability company hold marketing authorization atripla european territory starting except limited number activities jointly managed parties longer coordinate detailing promotional activities european territory responsible manufacturing product distribution inventory management warehousing primary responsibility regulatory activities local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets september bms elected voluntarily terminate agreement effective march post termination bms permitted commercialize atripla european territory entitled receive us certain fees based net sales atripla declining annual scale threeyear period following effective date termination collaboration arrangements individually significant entered several collaborative similar arrangements including equity investments licensing arrangements consider individually material cash outflows related arrangements totaled million million years ended december respectively recorded upfront collaboration licensing expenses related arrangements million million years ended december respectively within research development expenses consolidated statements income remaining amounts recorded current longterm assets consolidated balance sheets made material cash payments related individually insignificant collaboration arrangements entered financial terms arrangements may required make payments upon achievement various developmental regulatory commercial milestones could significant future milestone payments reflected consolidated statements income corresponding events become probable addition may required pay significant royalties future sales products related arrangements commercialized payment amounts however contingent upon occurrence various future events high degree uncertainty occurrence debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions december type borrowing issue date due date interest rate senior unsecured september march month libor senior unsecured march april senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net less current portion total longterm debt net senior unsecured notes enter borrowings connection acquisition kite issued billion aggregate principal amount senior unsecured notes million principal balance repaid maturity remaining billion repaid maturity collectively refer senior unsecured notes issued september notes september notes march november notes march december notes senior notes repaid maturity million billion principal balance related notes notes respectively february repaid maturity million principal balance related notes senior notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus make whole premium defined indenture senior notes maturing also call feature exercisable option redeem notes par whole part one six months immediately preceding maturity case accrued unpaid interest also required redeemed date redemption event occurrence change control downgrade rating senior notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants senior notes december violation covenants interest expense senior notes related contractual coupon rates amortization debt discount issuance costs billion billion billion respectively credit facilities connection acquisition kite borrowed billion term loan credit facility billion repaid remaining billion repaid term loan credit facility agreement terminated entered billion fiveyear revolving credit facility agreement maturing may fiveyear revolving credit agreement revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative covenants events default december violation covenants loans fiveyear revolving credit agreement bear interest either eurodollar rate plus applicable percentage ii base rate plus applicable percentage defined fiveyear revolving credit agreement may terminate reduce commitments may prepay loans fiveyear revolving credit agreement whole part time without premium penalty contractual maturities financing obligations december aggregate future principal maturities financing obligations next five years based contractual due dates follows millions contractual maturities leases operating leases consist primarily properties equipment administrative manufacturing rd activities determine arrangement contains lease inception rightofuse assets lease liabilities recognized commencement date based present value lease payments lease term noncancelable period stated contract adjusted options extend terminate reasonably certain exercise option leases include options extend terms years include options terminate lease within one year lease commencement date rightofuse assets adjusted prepaid lease payments lease incentives initial direct costs incurred december material finance leases operating leases provide implicit interest rate generally utilize collateralized incremental borrowing rate applied portfolio approach relevant based information available commencement date determine lease liability operating lease expense minimum lease payments recognized straightline basis lease term operating lease expenses including variable costs shortterm leases million year ended december operating lease expense prior lease standard million million years ended december respectively following table summarizes balance sheet information related operating leases december millions except weighted average amounts classification amount rightofuse assets net longterm assets lease liabilities current accrued liabilities lease liabilities noncurrent longterm obligations weighted average remaining lease term years weighted average discount rate following table summarizes supplemental information related operating leases millions year ended december cash paid amounts included measurement lease liabilities rightofuse assets obtained exchange lease liabilities following table summarizes maturity analysis operating lease liabilities showing aggregate lease payments december millions fiscal year amount thereafter total undiscounted lease payments less imputed interest total discounted lease payments following table summarizes aggregate undiscounted noncancelable future minimum lease payments operating leases prior lease standard december millions fiscal year amount thereafter total minimum lease payments commitments contingencies legal proceedings party various legal actions significant described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted possible determine outcome matters reasonably estimate maximum potential exposure range possible loss material accruals matters described consolidated balance sheets december litigation related sofosbuvir acquired pharmasset inc pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv received approval fda sofosbuvir known commercially sovaldi sofosbuvir also included marketed hcv products received number litigation claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringes us patent patent prevailed phases litigation concerning patent us supreme court denied idenixs petition certiorari also idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringes us patent nos patent patent court transferred massachusetts litigation us district court district delaware prior trial idenix committed give us covenant sue respect claims arising patent related sofosbuvir withdrew patent trial jury trial held patent jury found willfully infringed asserted claims patent awarded idenix billion past damages judge invalidated idenixs patent vacated jurys award billion past damages idenix appealed decision us court appeals federal circuit cafc october cafc issued opinion affirming trial courts decision patent invalid idenix petitioned rehearing cafc en banc may seek review us supreme court litigation university minnesota university minnesota university obtained us patent patent purports broadly cover nucleosides antiviral anticancer activity university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir court granted motion transfer case california also filed four petitions inter partes review us patent trademark office uspto patent trial appeal board ptab alleging asserted claims invalid anticipation obviousness us district court northern district california stayed litigation ptab rules petitions inter partes review litigation related axicabtagene ciloleucel patents patent applications protect axicabtagene ciloleucel chimeric dna segments third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing axicabtagene ciloleucel require us obtain license order commercialize axicabtagene ciloleucel october juno therapeutics inc sloan kettering cancer center collectively juno filed lawsuit us us district court central district california alleging commercialization axicabtagene ciloleucel sold commercially yescarta infringes us patent patent jury trial held patent december jury found asserted claims patent valid willfully infringed asserted claims patent jury also awarded juno damages amounts million upfront payment running royalty october date jurys verdict parties filed posttrial motions january file briefing first quarter expect judge rule matters later district court issued rulings entered judgment case may appealed cafc although predict certainty ultimate outcome litigation believe jurys verdict error also believe errors made court respect certain rulings trial assessing whether accrue liability litigation consolidated financial statements considered various factors including legal factual circumstances case jurys verdict district courts pre posttrial orders current status proceedings applicable law views legal counsel likelihood jurys verdict upheld appeal result review determined accordance applicable accounting standards probable incur material loss result litigation jurys verdict upheld appeal loss zero jurys verdict upheld entirety appeal estimate upper end range possible loss december approximately billion consists million upfront payment determined jury ii approximately million represents estimated royalties adjusted revenues yescarta october december iii enhanced damages requested juno two times sum ii result jurys finding willfulness sum excludes costs pre judgment interest supplemental damages consisting royalties sales yescarta december date judgment could subject royalty jurys verdict prospective royalty proposed juno enhancement postjudgment sales yescarta would subject prospective royalties estimated could would payable adjusted yescarta revenues judgment expiry patent august expect judge rule amount prospective royalties enhanced damages course deciding posttrial motions courts determination prospective royalties enhanced damages also appealed litigation related bictegravir viiv healthcare company viiv filed lawsuit us us district court delaware alleging commercialization bictegravir sold commercially combination tenofovir alafenamide emtricitabine biktarvy infringes viivs us patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid court set trial date september lawsuit viiv also filed lawsuit us federal court canada alleging activities relating bictegravir compound infringed viivs canadian patent patent issued shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claims patent january court held summary trial assess viivs infringement allegations courts decision expected march november december viiv filed lawsuits france germany ireland uk asserting relevant national designations european patent australia asserting australian patent japan asserting japanese patent korea asserting korean patent nos patents relate molecules viiv claim would act integrase inhibitors believe bictegravir infringe claims viivs patents jurisdictions extent claims viivs patents interpreted cover bictegravir believe claims invalid predict ultimate outcome intellectual property claims related bictegravir litigation relating preexposure prophylaxis august filed petitions requesting inter partes review us patent nos patent patent collectively hhs patents ptab hhs patents assigned us department health human services purport claim process protecting primate host infection immunodeficiency retrovirus administering combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus process commonly known preexposure prophylaxis prep november us department justice filed lawsuit us us district court delaware alleging sale truvada descovy use prep infringes hhs patents february ptab declined institute petitions inter partes review hhs patents although predict certainty ultimate outcome litigation believe truvada descovy infringe hhs patents hhs patents invalid prior art descriptions truvadas use prep postexposure prophylaxis physicians patients using claimed methods years centers disease control prevention filed applications patents litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products earlier patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval starting december received letters lupin ltd apotex inc shilpa medicare ltd sunshine lake pharma co ltd laurus labs natco pharma ltd cipla ltd collectively generic manufacturers indicating submitted andas fda requesting permission market manufacture generic versions certain tenofovir alafenamide tafcontaining products generic manufacturers seek market generic versions odefsey descovy vemlidy generic manufacturers challenged validity four patents listed orange book associated taf others challenged validity two orange booklisted patents associated taf evaluating letters intend enforce defend intellectual property european patent claims several parties filed oppositions european patent office epo requesting revocation one granted european patents covering sofosbuvir expires epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal hearing scheduled july several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires epo conducted oral hearing opposition upheld claims two original opposing parties appealed requesting full revocation several parties filed oppositions epo requesting revocation granted european patent covering taf expires epo upheld validity claims taf patent three parties appealed decision several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires epo upheld validity claims taf hemifumarate patent three parties appealed decision three parties filed oppositions epo requesting revocation granted european patent covering cobicistat expires epo upheld validity claims cobicistat patent two parties appealed decision appeal process may take several years epo opposition proceedings confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf taf hemifumarate cobicistat european union could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted european medicines agency lose patent protection compounds revenues results operations could negatively impacted years including succeeding year exclusivity lost government investigations related litigation received subpoena us attorneys office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry us department justice informed us following investigation declined intervene false claims act lawsuit filed two former employees also former employees served first amended complaint us district court northern district california issued order granting entirety without prejudice motion dismiss first amended complaint plaintiffs filed second amended complaint district court issued order granting motion dismiss second amended complaint plaintiffs filed notice appeal us court appeals ninth circuit ninth circuit ninth circuit granted motion stay case pending appeal us supreme court filed petition writ certiorari us supreme court solicitor general submitted brief united states us supreme court stating intention file motion dismiss federal false claims act january us supreme court denied petition case remanded district court march department justice filed motion dismiss second amended complaint district court granted department justices motion dismiss november dismissing relators federal false claims act claims received subpoena us attorneys office district massachusetts requesting documents related support c organizations provide financial assistance patients documents concerning provision financial assistance patients hcv products cooperating inquiry received subpoena us attorneys office district massachusetts requesting documents related copay coupon program medicaid price reporting methodology cooperating inquiry received voluntary request information us attorneys office eastern district pennsylvania requesting information related reimbursement support offerings clinical education programs interactions specialty pharmacies sovaldi harvoni received another voluntary request information related speaker programs advisory boards hcv hepatitis b virus products cooperating voluntary requests october us department justice informed us following investigation declined intervene false claims act lawsuit us relating hepatitis b speaker programs advisory boards brought two plaintiffs us district court eastern district pennsylvania notwithstanding governments declination plaintiffs continued pursue lawsuit served us seconded amended complaint november although predict ultimate outcome lawsuit believe action without merit intend vigorously defend received subpoena california department insurance alameda county district attorneys office requesting documents related marketing activities reimbursement support offerings clinical education programs interactions specialty pharmacies harvoni sovaldi cooperating inquiry also received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry product liability named defendant one class action lawsuit various product liability lawsuits related viread truvada atripla complera stribild plaintiffs allege viread truvada atripla complera andor stribild caused suffer kidney andor bone injuries lawsuits pending state federal court california delaware florida involve thousands plaintiffs plaintiffs cases seek damages relief various grounds alleged personal injury economic loss intend vigorously defend actions believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages antitrust consumer protection along japan tobacco bms johnson johnson inc named defendants class action lawsuit filed related various drugs used treat hiv including drugs used combination antiretroviral therapy plaintiffs allege defendants engaged various conduct restrain competition violation federal state antitrust laws state consumer protection laws lawsuit consolidated action pending us district court northern district california seeks bring claims behalf nationwide class endpayor purchasers similar lawsuit also recently filed us district court southern district florida may also consolidated plaintiffs seek damages permanent injunctive relief relief intend vigorously defend action believe action without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages could subject permanent injunctive relief matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients api certain inventory related items december commitments next five years approximately million million million million million amounts related api represent minimum purchase commitments actual payments purchases api certain inventory related items million billion billion january amended api contract increased firm purchase commitments approximately million stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions december remaining authorized repurchase amount program billion following table summarizes stock repurchases program millions except per share amounts year ended december shares repurchased retired amount average price per share addition repurchases program repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations immaterial excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated additional paidin capital apic based estimated average sales price per issued share excess amounts charged retained earnings following table summarizes reduction common stock apic charge retained earnings result stock repurchases millions year ended december reduction common stock apic charge retained earnings first quarter board directors authorized new billion stock repurchase program program commence upon completion program purchases program may made open market privately negotiated transactions dividends following table summarizes cash dividends declared common stock millions except per share amounts dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total restricted stock performance share awards units dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income following table summarizes changes aoci component net tax millions unrealized gains losses unrealized gains foreign currency availableforsale losses translation debt securities cash flow hedges total balance december reclassifications retained earnings result adoption new accounting standards balance january net unrealized loss gain reclassifications net income net current period comprehensive loss income balance december net unrealized gain reclassifications net income net current period comprehensive income loss balance december amounts reclassified net income gains losses cash flow hedges recorded part product sales consolidated statements income see note derivative financial instruments additional information amounts reclassified net income gains losses availableforsale debt securities recorded part income expense net consolidated statements income income tax impact allocated component comprehensive income material period presented employee benefits provide sharebased compensation form various types equitybased awards including restricted stock units rsus performance share awards units psus stock options compensation expense recognized consolidated statements income based estimated fair value award grant date estimated fair value rsus based closing price common stock psus estimated fair value based either monte carlo valuation methodology stock price date grant stock option awards estimated fair value based blackscholes option valuation model equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan amended plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance share awards employees directors consultants plan authorized issuance total million shares common stock december total million shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options stock options granted january nonqualified stock options employee stock options generally vest three four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value millions dollars years millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million million weightedaverage grant date fair value stock options granted per share per share per share weightedaverage grant date fair value stock options granted higher due replacement awards granted connection acquisitions kite cell design labs december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years restricted stock performance share awards grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus sharebased awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant fair value rsu equal closing price common stock grant date grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one two year period fair value award equal closing price common stock grant date following table summarizes rsu psu activity related information millions except per share amounts rsus psus weighted weighted average average grant date fair value grant date fair value shares per share shares per share outstanding december granted vested forfeited outstanding december weightedaverage grantdate fair value per share excludes shares related grants currently grant date performance objectives yet defined weightedaverage grant date fair value rsus granted per share per share per share weightedaverage grant date fair value psus granted per share per share per share total grant date fair value vested rsus psus million million million total fair value respective vesting dates million million million december million unrecognized compensation cost related unvested rsus psus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan international employee stock purchase plan together amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers sixmonth lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares million shares issued espp million total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation following table summarizes total stockbased compensation expenses included consolidated statements income millions year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax income tax effect year ended december included million income tax expense following us court appeals decision altera corp v commissioner requires related parties intercompany cost sharing arrangement share expenses related stockbased compensation see income taxes additional information stockbased compensation recognized expense requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience requisite service period could shorter vesting period employee retirement eligible valuation assumptions fair value options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million december million december net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents determined treasury stock method potential shares common stock excluded computation diluted net income per share attributable gilead common shareholders effect would antidilutive million million million respectively following table shows calculation basic diluted net income per share attributable gilead common stockholders millions except per share amounts year ended december net income attributable gilead shares used per share calculation basic dilutive effect stock options equivalents shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted segment information one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need chief executive officer ceo chief operating decisionmaker manages allocates resources operations company entitywide basis managing allocating resources entitywide basis enables ceo assess overall level resources available best deploy resources across functions rd projects based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities best support longterm growth business see note revenues summary disaggregated revenues product geographic region revenues major customers following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december amerisourcebergen corp cardinal health inc mckesson corp longlived assets net book value property plant equipment less office computer equipment united states billion december billion december billion december corresponding amount international locations million december million december million december individual international locations accounted less total balances income taxes income provision income taxes consists following millions year ended december domestic foreign income provision income taxes provision income taxes consists following millions year ended december federal current deferred state current deferred foreign current deferred provision income taxes provision income taxes included billion deferred tax benefit related intangible asset transfers foreign subsidiary ireland united states fourth quarter completed intraentity asset transfer certain intangible assets foreign subsidiary ireland transaction resulted stepup irish taxdeductible basis transferred assets accordingly created temporary difference tax basis exceeded book basis intangible assets result recognized deferred tax asset billion consolidated financial statements tax deductions amortization assets recognized future amortization deducted tax purposes carried forward indefinitely irish tax laws expect able realize deferred tax asset resulting intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material provision income taxes included million deferred tax charge related transfer acquired intangible assets foreign subsidiary united states transaction result stepup us taxdeductible basis result recognized deferred tax liability million temporary difference book basis exceeded tax basis acquired intangible assets provision income taxes included billion provisional charge income tax expense related tax reform enacted december tax reform made significant changes internal revenue code amended include limited corporate tax rate decrease effective tax years beginning december repatriation tax deemed repatriated earnings foreign subsidiaries implementation modified territorial tax system effect subjecting earnings foreign subsidiaries us taxation gilti elected account tax gilti period cost method reconciliation federal statutory tax rate applied income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings deferred tax intraentity transfer intangible assets transition tax deferred tax revaluation settlement tax examinations effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows millions december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible excess tax basis book basis intangible assets upfront milestone payments research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities property plant equipment excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax assets liabilities valuation allowance million million december respectively decrease valuation allowance primarily related reduction net operating loss carryforwards asset recognition framework corresponding valuation allowance respect certain foreign jurisdictions december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss start expire utilized state tax credit carryforwards carried forward indefinitely utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns united states many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits billion billion december recognized would reduce effective tax rate period recognition interest penalties related unrecognized tax benefits included part provision income taxes consolidated statements income million year ended december interest penalties related unrecognized tax benefits years ended december respectively material accrued interest penalties related unrecognized tax benefits million million december respectively december believe reasonably possible unrecognized tax benefits may materially change next months due potential resolutions tax authority estimate range reasonably possible change determined time june ninth circuit court appeals ninth circuit issued opinion altera corp v commissioner reversing prior decision united states tax court requiring related parties intercompany costsharing arrangement share expenses related stockbased compensation july taxpayer requested rehearing full ninth circuit request denied november result recorded cumulative income tax expense million fourth quarter february taxpayer requested hearing supreme court united states although final outcome case still uncertain recorded income tax expense fourth quarter based ninth circuits denial following rollforward total gross unrecognized tax benefits millions year ended december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period selected quarterly financial information unaudited millions except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income loss net income loss attributable gilead net income loss per share attributable gilead common stockholders basic net income loss per share attributable gilead common stockholders diluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted amounts third quarter included upfront collaboration licensing expenses billion per basic diluted share related collaboration galapagos see note collaborative arrangements additional details amounts fourth quarter included billion favorable tax effect related intraentity intangible asset transfers million pretax net gains equity securities partially offset million pretax impairment charge related inprocess research development iprd intangible assets acquired connection acquisition kite pretax writedowns million slow moving excess raw material work process inventory see note fair value measurements note inventories note intangible assets note income taxes additional details amounts fourth quarter included net favorable impact per basic share per diluted share factors noted footnote amounts fourth quarter included million pretax impairment charge related iprd intangible assets acquired connection acquisition kite million noncash tax charge related transfer acquired intangible assets foreign subsidiary united states pretax writedowns million excess raw materials primarily due sustained decrease demand harvoni see note inventories note intangible assets note income taxes additional details amounts fourth quarter included unfavorable impact per basic share per diluted share factors noted footnote gilead sciences inc schedule ii valuation qualifying accounts millions balance beginning additionscharged balance end period expense deductions period year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets allowances doubtful accounts cash discounts chargebacks item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san jose california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers applicable delinquent section reports written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading equity compensation plan information section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item